Matches in SemOpenAlex for { <https://semopenalex.org/work/W48752276> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W48752276 endingPage "6" @default.
- W48752276 startingPage "41" @default.
- W48752276 abstract "There is a growing body of evidence that the renin-angiotensin system (RAS) plays a pivotal role in the pathogenesis of cardiovascular diseases. Indeed, large clinical trials have demonstrated a substantial benefit of the blockade of this system for cardiovascular-organ protection. Although several types of angiotensin II type 1 (AT1) receptor blockers (ARBs) are commercially available for the treatment of patients with hypertension, comparisons of the binding affinity to AT1 receptor among them remain to be elucidated. In this study, we examined the dissociation rate of several ARBs from AT1 receptor in vitro. Angiotensin II time-dependently dissociated telmisartan, olmesartan, candesartan, valsartan, losartan and an active metabolite of losartan, EXP3174, from membrane components containing human AT1 receptor The dissociation rate constant of each ARB was 0.003248, 0.004171, 0.005203, 0.009946, 0.01027 and 0.008561 min(-1), with corresponding half-lives of 213, 166, 133, 70, 67 and 81 min, respectively. These results demonstrate that telmisartan has the strongest binding affinity to AT1 receptor among various ARBs examined herein. The rank order of affinity was telmisartan > olmesartan > candesartan > EXP3174 > or = valsartan > or = losartan. The present findings suggest that telmisartan (Micardis) may have long-lasting blood pressure-lowering effects and superior cardioprotective properties in patients with hypertension due to its strongest AT1 receptor antagonistic ability." @default.
- W48752276 created "2016-06-24" @default.
- W48752276 creator A5003019007 @default.
- W48752276 creator A5011693789 @default.
- W48752276 creator A5055844067 @default.
- W48752276 creator A5082962828 @default.
- W48752276 date "2005-01-01" @default.
- W48752276 modified "2023-09-25" @default.
- W48752276 title "Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers." @default.
- W48752276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15864875" @default.
- W48752276 hasPublicationYear "2005" @default.
- W48752276 type Work @default.
- W48752276 sameAs 48752276 @default.
- W48752276 citedByCount "50" @default.
- W48752276 countsByYear W487522762012 @default.
- W48752276 countsByYear W487522762013 @default.
- W48752276 countsByYear W487522762014 @default.
- W48752276 countsByYear W487522762015 @default.
- W48752276 countsByYear W487522762016 @default.
- W48752276 countsByYear W487522762017 @default.
- W48752276 countsByYear W487522762018 @default.
- W48752276 countsByYear W487522762020 @default.
- W48752276 countsByYear W487522762022 @default.
- W48752276 countsByYear W487522762023 @default.
- W48752276 crossrefType "journal-article" @default.
- W48752276 hasAuthorship W48752276A5003019007 @default.
- W48752276 hasAuthorship W48752276A5011693789 @default.
- W48752276 hasAuthorship W48752276A5055844067 @default.
- W48752276 hasAuthorship W48752276A5082962828 @default.
- W48752276 hasConcept C104849204 @default.
- W48752276 hasConcept C123915805 @default.
- W48752276 hasConcept C126322002 @default.
- W48752276 hasConcept C134018914 @default.
- W48752276 hasConcept C170493617 @default.
- W48752276 hasConcept C185592680 @default.
- W48752276 hasConcept C198710026 @default.
- W48752276 hasConcept C2777387769 @default.
- W48752276 hasConcept C2779716603 @default.
- W48752276 hasConcept C2779766728 @default.
- W48752276 hasConcept C2780036600 @default.
- W48752276 hasConcept C2780288358 @default.
- W48752276 hasConcept C2780708007 @default.
- W48752276 hasConcept C2908929049 @default.
- W48752276 hasConcept C71924100 @default.
- W48752276 hasConcept C84393581 @default.
- W48752276 hasConcept C98274493 @default.
- W48752276 hasConceptScore W48752276C104849204 @default.
- W48752276 hasConceptScore W48752276C123915805 @default.
- W48752276 hasConceptScore W48752276C126322002 @default.
- W48752276 hasConceptScore W48752276C134018914 @default.
- W48752276 hasConceptScore W48752276C170493617 @default.
- W48752276 hasConceptScore W48752276C185592680 @default.
- W48752276 hasConceptScore W48752276C198710026 @default.
- W48752276 hasConceptScore W48752276C2777387769 @default.
- W48752276 hasConceptScore W48752276C2779716603 @default.
- W48752276 hasConceptScore W48752276C2779766728 @default.
- W48752276 hasConceptScore W48752276C2780036600 @default.
- W48752276 hasConceptScore W48752276C2780288358 @default.
- W48752276 hasConceptScore W48752276C2780708007 @default.
- W48752276 hasConceptScore W48752276C2908929049 @default.
- W48752276 hasConceptScore W48752276C71924100 @default.
- W48752276 hasConceptScore W48752276C84393581 @default.
- W48752276 hasConceptScore W48752276C98274493 @default.
- W48752276 hasIssue "1" @default.
- W48752276 hasLocation W487522761 @default.
- W48752276 hasOpenAccess W48752276 @default.
- W48752276 hasPrimaryLocation W487522761 @default.
- W48752276 hasRelatedWork W137606157 @default.
- W48752276 hasRelatedWork W1976929788 @default.
- W48752276 hasRelatedWork W2007688337 @default.
- W48752276 hasRelatedWork W2073244528 @default.
- W48752276 hasRelatedWork W2075860162 @default.
- W48752276 hasRelatedWork W2097957153 @default.
- W48752276 hasRelatedWork W3193972101 @default.
- W48752276 hasRelatedWork W330879772 @default.
- W48752276 hasRelatedWork W48752276 @default.
- W48752276 hasRelatedWork W2292165629 @default.
- W48752276 hasVolume "25" @default.
- W48752276 isParatext "false" @default.
- W48752276 isRetracted "false" @default.
- W48752276 magId "48752276" @default.
- W48752276 workType "article" @default.